US FDA accepts Bristol Myers Squibb’s sNDA for Sotyktu to treat adults with active psoriatic arthritis: Princeton, New Jersey Tuesday, July 22, 2025, 12:00 Hrs [IST] Bristol Mye ...

FDA fast-tracks DB-1310, a novel HER3-targeting ADC, offering hope for advanced NSCLC patients with unmet treatment needs.

Panelists discuss how BTK inhibitors represent a promising new oral therapy class that could address both inflammatory and ...

Superior efficacy shown in two head-to-head phase III trials, including overall survival in DREAMM-7  Blenrep combinations ...

AstraZeneca announces positive results from FLAURA2 phase III trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer: Cambridge, UK Tuesday, July 22, 2025, ...

Panelists discuss how payers can evaluate BTK inhibitors by considering specific MS phenotypes and FDA indications rather ...

A groundbreaking study led by researchers at the Masonic Medical Research Institute (MMRI) has identified a promising ...

AMP-activated protein kinase (AMPK) plays a central role in maintaining energy balance in cells, especially under energy stress.

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

Cytokine networks demonstrate dual functionality. Cytokines are key regulators of immune homeostasis, but paradoxically, cytokines also function as pathogenic drivers in diseases such as systemic ...